Archived Webinar: PrEP 2.0: TDF/FTC and Beyond – State of the Science and the Product and Delivery System Pipeline

Archived Webinar:
PrEP 2.0: TDF/FTC and Beyond – State of the Science and the Product and Delivery System Pipeline

Raphael J. Landovitz, MD

Release date: June 25 2019
Expiration date: June 25, 2020
CME Credit Available: 1.25 AMA PRA Category 1 Credits


Assessment of Needs

The IAS–USA offers this free state-of-the-art activity as part of a nationwide continuing medical education (CME) effort for physicians on the evolving challenges of managing HIV disease. We will review the current state of the evidence for daily and “on-demand” or “2-1-1” TDF-based PrEP, with a particular emphasis on differences in best practices based on route of HIV exposure.  In follow-up, we will also consider the near- and far-term pipelines for novel agents promising for use as PrEP, as well as novel delivery systems and timelines for anticipated evidence being available.  Finally, we will look at some challenges of making new/incident HIV diagnoses in the context of TDF-based PrEP.  The webinar will present Insights and approaches to troubleshooting difficult cases, and we will close with some forward-looking caveats about diagnosing new/incident infections in the context of the anticipated PrEP pipeline.

Learning Objectives

On completion of this webinar, learners will be able to:

  • Describe the current evidence for the efficacy of TDF-based PrEP (daily and “on-demand”)
  • Describe the range of PrEP agents currently in development
  • Describe the challenges with HIV infection diagnosis in the PrEP context


Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”


Dr Landovitz has served as a consultant to Gilead Sciences, Inc, Merck & Co, Inc, and Roche. (Updated 06/25/19)

CME Planner and Reviewer

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 06/25/19)

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

Additional support has been provided by
Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at” or 415-544-9400.

Course Materials

How to Claim Credit

  1. Start the Activity by clicking "START COURSE" located above.
    Please note that the "START COURSE" will no longer be visible once you clicked it once.
  2. Watch the webinar here.
  3. Return to this page and follow this link to the evaluation form.
  4. Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
  5. Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.